

Seneca Therapeutics is pleased to welcome Zachary Morris, MD, PhD, to its Clinical Advisory Board. Dr. Morris will work closely with Dr. Paul Hallenbeck, founder and CEO of Seneca Therapeutic, Inc. as the company is on target to begin a Phase II Clinical Ready trial with its leading candidate, SVV in a combination immunotherapeutic treatment for patients with cancer. The Phase II Ready clinical trial is set to begin in early 2020.

As a physician-scientist, Dr. Morris' current clinical focus is on the treatment of patients with melanoma and soft tissue sarcomas. Dr. Morris' independent translational research laboratory focuses on the mechanisms whereby radiation may enhance the response to immunotherapies.

Dr. Morris is an assistant professor and vice chair of the Department of Human Oncology at the University of Wisconsin. He is originally from Rockford, Ill., and completed his undergraduate studies at Ripon College in Ripon, Wisconsin. Dr. Morris earned two Master's degrees (Medical Anthropology and History of Science, Medicine, and Technology) at Oxford University as a Rhodes Scholar. He completed his MD at Harvard Medical School and earned a PhD at Harvard University in the Biological and Biomedical Sciences Program, where he successfully performed thesis research in the laboratory of Prof. Andrea McClatchey.

Dr. Morris completed a preliminary year internship in internal medicine at the University of Hawaii and then completed his residency training in radiation oncology at the University of Wisconsin Hospitals and Clinics. Under the American Board of Radiology's Holman Pathway, he spearheaded a collaborative research project during his residency in the labs of Prof. Paul Sondel and Prof. Paul Harari.